Crysta IVF is a reproductive health startup based in India, part of Redcliffe Life Sciences, that offers IVF and fertility services.

This Startup Deep Dive explains what Crysta IVF does, how it makes money, who backs it, how it compares with rivals and what could go wrong, using publicly available information. It is educational and not investment advice. Last updated: October 2026.

Crysta IVF in Brief

• What it is: Crysta IVF is an Indian Fertility and IVF company based in New Delhi.
• Who it serves: patients, doctors, hospitals, diagnostic centres, insurers and employers.
• Crysta started as a reproductive health brand offering pre-conception and fertility tests, non-invasive prenatal screening, clinical microarray, pre-implantation genetic screening for IVF centres, and carrier and newborn screening.
• It later became a fertility chain offering IVF, IUI, embryology and surrogacy services through partner clinics in several cities.
• Reports on scale differ: 30+ centres (company claim in 2021), 19+ centres in 15+ cities (a directory) and about 6 named cities on a financing partner page.
• Funding: Rs 10 crore (about $1.3M to $1.41M depending on database).

Crysta IVF Quick Facts

Figures marked “reported” come from published reports and may differ between sources; “Not disclosed” means no reliable public figure was found.

What Is Crysta IVF?

Crysta IVF operates in the Fertility and IVF space in India. Understanding a company like this starts with three questions: who is the customer, what painful problem is being solved, and why the solution is better than the alternatives. The sections below apply that lens to Crysta IVF.

• Crysta started as a reproductive health brand offering pre-conception and fertility tests, non-invasive prenatal screening, clinical microarray, pre-implantation genetic screening for IVF centres, and carrier and newborn screening.
• It later became a fertility chain offering IVF, IUI, embryology and surrogacy services through partner clinics in several cities.
• Reports on scale differ: 30+ centres (company claim in 2021), 19+ centres in 15+ cities (a directory) and about 6 named cities on a financing partner page.

The Origin Story of Crysta IVF

Every company starts from a noticed gap and a team willing to commit to closing it. Strong origin stories are specific: a clear problem, a founding team with relevant skills, and an early product that real customers could test. Founder-market fit, meaning the team’s lived experience or technical depth in the domain, tends to predict how fast a young company learns.

• Founders: Dheeraj Jain, Ashish Dubey, Harshita Jain.
• Crysta is linked to Redcliffe Life Sciences, a genomics and diagnostics company founded in 2018 by Dheeraj Jain with Ashish Dubey as co-founder.
• Press coverage names Dheeraj Jain consistently as founder of Crysta IVF; a 2021 item adds Harshita Jain as co-founder and a database lists Ashish Dubey.
• The 2020 funding was meant to build an end-to-end reproductive health platform and to improve Redcliffe's reach and technology.

Key Milestones and Challenges

No startup grows in a straight line. Early years usually involve slow adoption, product rewrites, hiring mistakes and funding gaps. In the Fertility and IVF sector the common turning points are a first paying customer, a regulatory approval, a successful product demonstration or a funding round that lets the team invest ahead of demand. How a team responds to setbacks says more about resilience than any single headline.

• January 2020: Rs 10 crore pre-Series A from the Jaipuria family offices and others.
• June 2021: opened centres in Delhi (with Fertile Solutions IVF and Research Center) and Mumbai (with Corion Fertility).
• August 2021: opened an Indore centre; claimed 30+ centres and a goal of 100 cities within two years.
• FY25: revenue of about Rs 46.6 crore, up about 86.5% on the prior year (reported by a database).

Crysta IVF Funding and Investors

Funding history shows how much outside confidence a company has attracted and how long it can operate before needing more capital. Figures below are reported and may differ between sources; valuation figures are estimates unless the company has confirmed them.

• Pre-Series A, January 2020, Rs 10 crore (about $1.4M), led by the family office of Ruchirans and Anuraag Jaipuria, with Green Shots Capital, Alfa Ventures, Real Time Ventures, NGB Diagnostics, Petrotech, Steel City Securities and angels including Lalit Wadhwa and Dr Kriti Maroli.
• A $10 million Series A was being prepared in 2020 for expansion in the mother and child segment; no closing was found.

How Does Crysta IVF Make Money? (Business Model)

A business model describes who pays, how often and how much it costs to serve them. Strong models show repeat usage, improving margins with scale and acquisition channels that do not depend only on paid spend. Weak models show one-off sales, rising costs and growth that stops when spending stops. For companies selling to patients, doctors, hospitals, diagnostic centres, insurers and employers, sales cycles and contract size matter as much as headline growth.

• Aggregator-style model: it partners with established IVF clinics and doctors and co-brands the centres, reducing its own capital spending (as described by investigative and database coverage).
• Generates patient demand through heavy digital marketing and a celebrity brand ambassador, then earns from treatment fees at partner centres.
• Earlier revenue came from fertility and genetic testing sold to IVF centres.

The Numbers: Crysta IVF Financials

Financial figures show whether growth is turning into a self-sustaining business. Small and private companies often disclose little, so any number below is included only if it was found in public reporting.

• FY25 revenue about Rs 46.6 crore, up about 86.45% (reported by a startup database).
• Employees: about 230 (reported by a database).
• Rs 10 crore raised in January 2020.

Market Opportunity for Crysta IVF

Market size is easy to exaggerate, so a useful approach separates the total market from the portion a company can realistically reach with its current product and distribution. The main forces behind demand in this sector are rising chronic disease, growing health insurance penetration, government programmes such as Ayushman Bharat and the Ayushman Bharat Digital Mission, and the shift of care to digital and home settings. Each of these widens the opportunity, but capital efficiency and execution decide who captures it.

• India has a large and growing infertility treatment market served by chains such as Indira IVF and Nova IVF.
• Crysta targeted tier 2 and tier 3 cities with a goal of 100 cities within two years (company-stated in 2021).

Technology and Product at Crysta IVF

Technology is rarely the whole moat, but it drives speed, cost and customer experience. A practical way to assess it is to separate the capability the company controls from the commodity infrastructure it rents. In this sector the important factors are clinical validity, data quality, integration with hospital and lab systems, and trust among doctors and patients.

• Diagnostics side uses biochemistry and molecular next-generation sequencing with its own bioinformatics platform (as of 2020).

Team and Culture at Crysta IVF

Teams are the most important and least measurable asset of a young company. Look at how complementary the founders’ skills are, how deep the second layer of leadership is, and how the company hires and retains specialists. Culture shows up in small repeated behaviours: how quickly bad news travels upward and whether commitments to customers are kept.

• Dheeraj Jain is founder; Ashish Dubey is named as co-founder by a database.
• Partner clinics are led by local doctors, for example the Indore centre by Dr Hemant Athavale and Dr Mangala Athavale.

Crysta IVF Competitors: Competitive Landscape

A fair competitive analysis names direct rivals, adjacent players who could move into the space, and the customer’s default alternative. Durable advantages include proprietary data or technology, licences and approvals, brand trust, switching costs and cost leadership.

Risks and Challenges for Crysta IVF

• The co-branded aggregator model has been described as operating in a legally grey area, and an investigative report linked the category to scrutiny under India's sex-selection law.
• Success-rate and centre-count claims are self-reported and not independently verified.
• Founder, founding year and footprint differ across sources.
• Heavy reliance on marketing spend and on partner clinic quality.
• Regulatory risk: medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules.
• Clinical and liability risk: errors in care, diagnosis or product quality can damage trust quickly.

Risk is not a reason to avoid a company; it is a reason to price it correctly and to monitor the right indicators over time. Regulation in this sector is shaped by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

Crysta IVF Growth Outlook: What to Watch

• 2021 plans: add 12 centres within months and reach 100 cities in two years (company-stated).
• Planned $10 million Series A in 2020; no confirmation found.
• Key indicators: patient or user volumes, repeat usage, gross margin, clinical outcomes and cost of acquiring each customer.
• Funding position: Whether Crysta IVF can reach its next milestone before needing new capital.
• Regulation: Changes from the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

Industry Context: Where Crysta IVF Fits

India's healthcare market combines a large public system, a fast-growing private hospital sector and an increasingly digital layer. Government initiatives such as Ayushman Bharat and the Ayushman Bharat Digital Mission aim to widen insurance cover and create common digital health records, while telemedicine guidelines and the Digital Personal Data Protection Act shape how digital care and patient data can be used.

Demand is driven by chronic and lifestyle disease, an ageing population, rising insurance penetration and consumers who now expect to book, pay and consult online. Startups in this field compete on trust, clinical quality and convenience, and they must prove outcomes and safety as well as growth.

For readers new to this field, a useful habit is to separate announcements from evidence. A plan, a partnership or a funding headline describes intent, while a delivered product, a paying customer or an audited financial statement describes results. Comparing the two over time shows how reliably a company turns promises into outcomes.

Bull Case and Bear Case for Crysta IVF

An investment thesis is a short, testable statement of why a company could become far more valuable, together with what evidence would prove it wrong. The points below are general to this sector and are not forecasts for Crysta IVF.

Bull case

• Rising insurance cover and digital adoption expand the customer base.
• Strong clinical evidence builds trust with doctors and hospitals.
• Scale can improve unit economics in diagnostics and care delivery.

Bear case

• Regulatory changes can alter permitted products or business models.
• Customer acquisition costs can erode margins.
• A single safety or privacy incident can damage trust.

Lessons Founders and Investors Can Take from Crysta IVF

Studying a company in the Fertility and IVF space offers lessons that go beyond any single firm. The points below are general lessons for the sector and are not claims about Crysta IVF.

• Trust is the real currency in healthcare, so quality control, clinical evidence and data protection must be built in from the start.
• Distribution through hospitals, clinics, insurers or employers can matter more than a standalone consumer app.
• Unit economics improve when repeat usage replaces expensive one-time customer acquisition.
• Regulatory approvals can take time, so timelines and cash planning should allow for them.
• Integration with existing hospital, lab and records systems reduces friction for adoption.

How to Evaluate Crysta IVF as a Startup

• Customer clarity: Can Crysta IVF name its customer and the problem it solves in one sentence?
• Evidence of demand: Look for repeat customers, signed contracts or measurable usage rather than announcements alone.
• Economics: Check whether margins improve as volume grows.
• Execution: Compare announced timelines with what has actually been delivered.
• Funding runway: Estimate how long current capital lasts at the present spending rate.
• Regulatory standing: Confirm required approvals are in place.
• Customer concentration: Check whether a few customers account for most of the revenue.
• Management depth: Look for experienced leaders beyond the founders and a stable core team.

The Takeaway

Crysta IVF is part of India’s growing Fertility and IVF ecosystem. The useful lesson from studying it is the discipline of asking structured questions about customers, economics, advantage and resilience. Companies that answer them well, repeatedly and under pressure are the ones that endure. Readers should treat any single report, ranking or funding headline as one input among many, and should re-check key facts against recent company announcements. Because public information on young companies is often limited, patience in verifying claims is part of good analysis. This article is educational and is not investment advice.

• Clear customers and repeat demand matter more than announcements.
• Regulation and capital needs shape how fast a startup in this sector can grow.
• Track a few leading indicators over time rather than one headline metric.

Crysta IVF FAQs: Frequently Asked Questions

What is Crysta IVF?

Crysta IVF is a reproductive health startup based in India, part of Redcliffe Life Sciences, that offers IVF and fertility services. It is profiled in the Startup Deep Dive series, which explains business model, funding, competitors and risks.

Who founded Crysta IVF?

Crysta IVF was founded by Dheeraj Jain, Ashish Dubey, Harshita Jain, and the company reports a founding year of reports differ: 2017, 2018, 2019 and 2021 in different profiles.

How much funding has Crysta IVF raised?

Rs 10 crore (about $1.3M to $1.41M depending on database). Funding figures are reported and may differ between sources, so readers should check the latest company announcements.

How does Crysta IVF make money?

Crysta IVF earns revenue from its Fertility and IVF products and services sold to patients, doctors, hospitals, diagnostic centres, insurers and employers. The exact revenue mix is described in the business model section and is not fully disclosed publicly.

Who are the competitors of Crysta IVF?

Reported rivals include Indira IVF, Nova IVF Fertility, Birla Fertility, Oasis IVF. See the competitor comparison above for how they differ.

What are the main risks for Crysta IVF?

Main risks include medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules, funding and capital needs, competition and regulation by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act. This is educational content, not investment advice.

Related Startup Deep Dives: LenDenClub — LenDenClub raised a $10M Series A in 2021 | Eyestem Research — Eyestem: Bengaluru stem cell therapy for blindness in Phase 2. Browse the full Startup Deep Dive series.

Source

Source: Publicly available data, published reports, industry research, and other credible sources.